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Abstract: 
Extended-spectrum β-lactamases (ESBLs) are the bacterial enzymes that make them resistant to advanced-generation cephalosporins. CTX-
M enzymes (the most prevalent ESBL-type) target cefotaxime. Aims of the study were: (i) Modelling of CTX-M enzyme from blaCTX-M 
sequences of clinical Escherichia coli isolates (ii) Docking of cefotaxime with modelled CTX-M enzymes to identify amino acid residues 
crucial to their interaction (iii) To hypothesize a possible relationship between ‘interaction energy of the docked enzyme-antibiotic complex’ 
and ‘minimum inhibitory concentration (MIC) of the antibiotic against the bacteria producing that enzyme’.  Seven E. coli strains of clinical 
origin which were confirmed as PCR-positive for blaCTX-M were selected for the study. C600 cells harboring cloned blaCTX-M were tested for 
ESBL-production by double-disk-synergy test. BLAST analysis confirmed all the blaCTX-M genes as blaCTX-M-15. Four of the 7 strains were 
found to be clonally related. Modelling was performed using Swiss Model Server. Discovery Studio 2.0 (Accelrys) was used to prepare 
Ramachandran plots for the modelled structures. Ramachandran Z-scores for modelled CTX-M enzymes from E. coli strains D8, D183, 
D253, D281, D282, D295 and D296 were found to be -0.449, 0.096, 0.027, 0.043, 0.032, -1.249 and -1.107, respectively. Docking was 
performed using Hex 5.1 and the results were further confirmed by Autodock 4.0. The amino acid residues Asn 104, Asn132, Gly 227, Thr 
235, Gly 236, and Ser237 were found to be responsible for positioning cefotaxime into the active site of the CTX-M-15 enzyme. It was 
found that cefotaxime MICs for the CTX-M-15-producers increased with the increasing negative interaction energy of the enzyme-antibiotic 
complex.  
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Background: 
Antibiotic resistance in bacteria is an increasing problem worldwide 
[1].
  Extended spectrum β-lactamases (ESBLs) are the bacterial 
enzymes that make them resistant to advanced generation 
cephalosporins and might lead to therapeutic dead-end. ESBLs are 
of due scientific concern because they are often plasmid-associated 
and there can be cross-species dissemination of these plasmids. 
Moreover, these plasmids often carry genes for co-resistance to 
other antibiotics such as aminoglycosides, fluoroquinolones, 
tetracyclines, chloramphenicol and sulfamethoxazole-trimethoprim. 
ESBLs hydrolyze the β-lactam ring present in the target antibiotics. 
CTX-M enzymes have become the most prevalent ESBLs [2] which 
mainly target cefotaxime. The change in activities of CTX-Ms 
leading to the evolution of more variants may be due to point 
mutations present either inside or outside of the active site omega 
loop (amino acid positions 161 to 179) [3]. Identification of the 
amino acid residues crucial to the interaction between CTX-M (the 
enzyme produced by resistant bacteria) and cefotaxime (the drug 
hydrolyzed by this bacterial enzyme) is a problem of deep scientific 
interest. This information might be useful for the scientists involved 
in drug-designing in their search for more potent and versatile CTX-
M inhibitors. A number of authors have explored the binding of 
different variants of CTX-M (other than CTX-M-15, which is being 
covered by the present study) with reference to structure and 
dynamics. Kimura et al [4] have described binding of cefotaxime to 
CTX-M-18 and CTX-M-19.   Notably, the authors observed that 
although the oxime side chain of cefotaxime does not have a 
carboxylate group to form hydrogen bond with Ser237, Ser237 kept 
an original conformation without a steric interaction with the 
methoxime in CTX-M-18. The C-4 carboxylate formed hydrogen 
bonds with Ser130 and Arg276. On the other hand, the steric 
interaction between the AT moiety and Ser167 in CTX-M-19 
invoked a conformational change of Ser237 to form a hydrogen 
bond with the C-4 carboxylate. Thus, the C-4 carboxylate formed 
the hydrogen bond with Ser130 in both CTX-M-18 and CTX-M-19. 
The authors highlighted that their results were compatible with the 
fact that both enzymes have a similar affinity for cefotaxime [4]. 
Regarding the inhibitors, sulbactam, clavulanate and tazobactam are 
traditional CTX-M inhibitors, while LN1-255 and NXL-104 [5] are 
novel inhibitors. Most of these share the same binding site as 
cefotaxime. For instance, sulbactam forms a dead-end-complex with 
CTX-M and renders it ineffective and occupies the same site as 
cefotaxime. To the best of our knowledge, there are no studies 
reporting modelling of CTX-M-15 variant of the CTX-M family 
and their docking with cefotaxime. Also, there was no X-ray 
crystallographic structure available with the Protein Data Bank for 
this variant of CTX-M family at the time of communicating this 
paper.In view of the stated background, we found it pertinent to 
study the mode of interaction of CTX-M enzyme with cefotaxime. 
This study is based on interaction energies. The objectives of the 
study were: (i) Modelling of CTX-M enzyme from blaCTX-M 
sequences of clinical Escherichia coli isolates (ii) Docking of 
cefotaxime with modelled CTX-M enzymes in order to identify 
amino acid residues crucial to their interaction (iii) To hypothesize a 
possible relationship between ‘interaction energy of the docked 
enzyme-antibiotic complex’ and ‘minimum inhibitory concentration 
(MIC) of the antibiotic against the bacteria producing that enzyme’.     
 
Methodology: 
Seven E. coli strains of clinical origin  which were confirmed as 
PCR-positive for blaCTX-M  were selected for the present study. 
Originally, 111 clinical E. coli isolates that gave a positive double-
disk synergy test for ESBL-production were screened for the 
presence of blaCTX-M gene by PCR. As these 7 strains were PCR-
positive for blaCTX-M, we narrowed down to the same from amongst 
these strains for further investigations. Strains D8, D183, D282, 
D295 and D296 were isolated from neonates admitted to neonatal 
intensive care unit of Aligarh Hospital, India. Strains D253 and 
D281 were isolated from infected foot ulcers of diabetic patients 
admitted to the endocrinology ward of the same hospital. The 
blaCTX-M genes which were amplified from clinical E. coli strains 
were cloned into E. coli C600 cells using ‘Qiagen cloningplus kit’ 
as per manufacturer’s instructions (Qiagen, USA). C600 
blaCTX-M 
cells were tested for ESBL-production by the double-disk synergy 
test performed as described by Jarlier et al [6].  Briefly the synergy 
test   with   ceftazidime,   cefotaxime, ceftriaxone and cefixime was 
performed by disk diffusion method  on Mueller-Hinton  agar   
plates  with  and  without  10  µg  of  amoxyclav.  A ≥ 5-mm 
increase in the zone of diameter of third generation cephalosporins, 
tested in combination with amoxyclav versus its zone when tested 
alone was considered indicative of ESBL production.  E. coli ATCC 
25922 was used as ESBL negative and Klebsiella pneumoniae 
700603 was used as ESBL positive reference strain. Also C600 
blaCTX-M cells were again tested for the presence of the said gene by 
PCR. Cefotaxime and ceftazidime MICs for the study strains were 
determined by the Clinical and Laboratory Standards Institute 
(CLSI)-microbroth dilution method. Antibiotic susceptibilities were 
tested by disk-diffusion method as per the CLSI guidelines for the 
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same. Transmissibility of cefotaxime and ceftazidime resistance 
markers was checked by transconjugation which was performed as 
described previously [7].  Enterobacterial repetitive intergenic 
consensus (ERIC)-PCR was used for the analysis of genetic 
relatedness of the seven selected strains as described by Versalovic 
et al [8].  BLAST-P was performed to retrieve suitable templates for 
homology modelling using the study blaCTX-M  sequences. Protein 
Data Bank (PDB) IDs of the templates retrieved for modelling are 
shown in table 1. Modelling was performed using Swiss Model 
Server [9]. The modelled structures (prior to docking) were verified 
using the “Structure Assessment” function of the Swiss Model 
Workspace which incorporates Procheck [10] and verify3D 
programmes [11]. PDB structure of cefotaxime was retrieved from 
Drug bank (Drug Bank accession no. DB00493).  The ligand 
(cefotaxime) was docked into each of the modelled structures 
employing the Hex 5.1 software. This program uses spherical polar 
Fourier correlation to accelerate docking calculations. However, 
since Hex 5.1 is generally considered a more reliable platform for 
“protein-protein  docking” compared to “protein-ligand” docking, 
we reconfirmed our results using the targeted docking mode of 
‘Molecular Docking Server’ which is based on the well known 
Autodock program. The MMFF94 force field was used for energy 
minimization of ligand molecules. Gasteiger partial charges were 
added to the ligand atoms. Non-polar hydrogen atoms were merged, 
and rotatable bonds were defined. Docking calculations were 
carried out on the protein models. Essential hydrogen atoms, 
Kollman united atom type charges, and solvation parameters were 
added with the aid of AutoDock tools. Affinity (grid) maps of 
60×60×60 Å grid points (centred on Ser237, a well identified 
residue of the active site) and 0.375 Å spacing were generated using 
the Autogrid program. AutoDock parameter set and distance-
dependent dielectric functions were used in the calculation of the 
van der Waals and the electrostatic terms, respectively. Docking 
simulations were performed using the ‘Lamarckian genetic 
algorithm (LGA)’ and the ‘Solis & Wets local search method’. Each 
docking experiment was derived from 10 different runs that were set 
to terminate after a maximum of 250000 energy evaluations. The 
population size was set to 150. During the search, a translational 
step of 0.2 Å, and quaternion and torsion steps of 5 were applied. 
The lowest-energy structures were selected as energy-refined 
complex models. The models were duly verified by Procheck [10] 
and verify3D programmes [11]. Discovery Studio 2.0 (Accelrys) 
was used to prepare Ramachandran plots for the modelled 
structures. Ramachandran Z-scores for the evaluation of these 
models were calculated using ‘WHAT IF’ package. Alignments 
were performed by ClustalW program using default parameters. 
 
 
Figure 1 (a) Ramachandran plot for the modelled CTX-M-15 enzyme corresponding to strain D8 (GenBank accession no. - FJ997864) (b) 
Interaction between cefotaxime and the modelled CTX-M-15 enzyme obtained by Hex5.1 (c) Modelled CTX-M-15 enzyme corresponding 
to strain D8 (d) Total interaction energy (Etotal) versus cefotaxime MIC graph for the study E. coli strains (Docking: Ligand = cefotaxime; 
Receptor = modelled CTX-M-15 enzymes). 
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Figure 2  Interaction between cefotaxime and the modelled CTX-M-15 enzyme obtained using Autodock4.0. The drug is shown in stick 
form. The broken lines represent hydrogen bonds. ‘Interacting amino acid residues’ are labeled. Figure has been produced by Discovery 
Studio2.0 
 
Discussion: 
BLAST analysis of the sequences confirmed all the blaCTX-M genes 
as  blaCTX-M-15. The gene sequences used in the study appear in 
GenBank with the following accession numbers: FJ997864, 
FJ997865,  FJ997866,  GQ145220,  GQ145221,  GQ174503 and 
GQ174504. The cefotaxime resistance markers were found to be 
located on the plasmid DNA of the study strains and were 
transmissible by conjugation. Conjugation frequencies were of the 
order 10
-5. Four out of the 7 study strains were found to be clonally 
related as revealed by their ERIC-profiles. The blaCTX-M-15 from 
strain D8 possessed point mutations 262C→A and 265A→G 
resulting in amino acid substitutions Pro88Thr and Asn89Asp 
respectively  (Table 1 in supplementary material). In the strain 
D295, blaCTX-M-15 possessed point mutation 689G→C leading to the 
amino acid substitution Val230Leu. Additional information 
regarding sequence-alignments and secondary structures is 
presented in supplementary files 1 and 2. Over 90% of the amino 
acid residues in the protein structures modelled from blaCTX-M-15 
genes were found to be present in the most favored regions as 
revealed by their respective Ramachandran plots. For instance, 
percent amino acid residues in most favored, additional allowed, 
generously allowed and disallowed regions of the Ramachandran 
plot for the modelled CTX-M enzyme corresponding to strain D8 
(GenBank accession no.- FJ997864) were 91.0%, 8.2%, 0.8% and 
0.0%, respectively (Figure 1a). All the enzyme structures were 
modelled using the PDB structure 1iysA as template. The target 
sequences possessed more than 80% sequence-identity with the said 
template. For instance, D8 CTX-M enzyme model was constructed 
using 1iysA (1.65Å) template with a sequence-identity of 85.326% 
(E value: 5.27e-83). Ramachandran Z-score expresses how well the 
backbone conformations of all the residues correspond to the known 
allowed areas in the Ramachandran plot. Accordingly, the 
Ramachandran Z-scores for modelled CTX-M enzymes from E. coli 
strains D8, D183, D253, D281, D282, D295 and D296 were found 
to be -0.449, 0.096, 0.027, 0.043, 0.032, -1.249 and -1.107, 
respectively. This further confirms the accuracy of the modelled 
structures. Cefotaxime was docked into each of these modelled 
enzyme-structures.  
 
The flexibility of the β3 strand, omega loop, and residues Ser-237, 
Asp-240, and Arg-276 are known to be involved in the 
cefotaximase activity of CTX-M enzymes [12]. It is reported that 
the β3 strand of CTX-M enzymes has numerous Gly residues and is 
therefore probably more flexible than that of TEM enzymes. 
Residue Gly-240 in CTX-M-15 may further increase the flexibility 
of the β3 strand and alter its positioning during the catalytic process. 
It is supposed that CTX-M-15 might have evolved from CTX-M-3 
due to a single amino acid change (D240G). As a result of this 
substitution (D240G), interaction between the residues Gly 240 and 
Asn 270 was found to be absent in the CTX-M-15 enzyme. The 
absence of this interaction in CTX-M-15 might increase the 
flexibility of the C-terminal of the β3 strand. During the catalytic 
process, this flexibility could favour the accommodation of more 
varied substrates with respect to their size and 3D-structures. This 
explanation is compatible with the fact that the CTX-M-15 enzyme 
is known to hydrolyze cefotaxime, ceftazidime as well as cefepime 
antibiotics quite efficiently. Moreover, these results are in coherence 
with the observation of several authors with reference to other CTX-
M-variants such as CTX-M-27 [13]. The SDN (positions 130-132), 
and KTG (positions 234-236) sequences, were found to be 
conserved in all the CTX-M-15 sequences obtained in this study. 
These are typical structure of class A enzymes [14].  A l l  t h e  
sequences harbored the D240G mutation with respect to CTX-M-3, 
the distinguishing feature of CTX-M-15 enzymes. None of the 
mutations obtained in our CTX-M-15 sequences lied within the 
omega loop or other positions that are known to affect the substrate 
profile of these enzymes. Hence the trend in the MIC values for 
cefotaxime and ceftazidime antibiotics in these isolates was typical 
of CTX-M-15 producers (Table 1 in supplementary material). 
The study isolates displayed cefotaxime MICs up to 8 fold higher 
than ceftazidime MICs, as observed previously [15]. Figure 1b and 
figure 2 show close-up view of interaction between cefotaxime and 
CTX-M-15 enzyme modelled from blaCTX-M-15  gene sequence of 
strain D8, as per the results of Hex5.1 and Autodock4.0, 
respectively. It is important to mention here that the docking results 
obtained by Hex 5.1 were in harmony with the results obtained 
using Autodock 4.0 but were not identical. All, the results with 
reference to energies and interacting residues were same, except that 
Autodock identified Asn104 also as one of the interacting residues. 
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Analysis of the docked structures by Discovery Studio2.0 was 
performed by using the “show ligand interactions” function of the 
“scripts” menu provided within the said software. It was revealed 
that the amino acid residues Asn 104, Asn132, Gly 227, Thr 235, 
Gly 236, and Ser237 were responsible for the proper positioning of 
cefotaxime into the active site of the CTX-M-15 enzyme, as per the 
Autodock results (which is generally considered to be more reliable 
than Hex5.1). This finding is supported by the views of other 
authors as well [16, 17]. Ramachandran Z-scores obtained by 
‘WHATIF’ for all the docked structures were well inside tolerable 
limits. For instance, Z-score of the docked complex involving CTX-
M enzyme model (corresponding to the strain D183) and 
cefotaxime, was found to be 0.390. Furthermore, the residues 
involved in the interaction constituted the same secondary structures 
as those involved in interaction of cefotaxime to closely related 
enzymes whose X-ray crystallographic structures are available with 
the ‘RCSB Protein Data Bank’.  Asn 132, one of the interacting 
residues forms part of a ‘loop’ in our study. Similarly, several 
crystallographic structures of Class A beta lactamases complexed 
with ligands, show Asn 132 as an interacting residue which 
constitutes a ‘loop’.  Our results (secondary structures constituted 
by the interacting residues as well as the docking pose) are in 
perfect harmony with the PDB entry 1IYO, which shows Toho-1 (a 
Class A beta-lactamase) in complex with cefotaxime. The first and 
last residues of the omega loop are clearly marked in Fig 1c, which 
are Arg161 and Asp179, respectively. Asn132, one of the residues 
important for positioning the drug into the active site of the enzyme 
is also shown in the figure as part of the ‘SDN’ loop (Figure 1c). 
Ser237 forms a hydrogen bond with the carboxylate oxygen of 
cefotaxime (Figure 2). This interaction might induce the rotation of 
the carboxylate group in the acyl-intermediate structure of CTX-M-
15 compared with those of non-ESBL enzymes. Interaction between 
Ser 237 and cefotaxime probably helps to bring the beta lactam 
carbonyl group to the suitable position in the oxyanion hole, thereby 
promoting drug-hydrolysis. The acylamide side chain of cefotaxime 
interacts with the N
δ of Asn132 and the backbone oxygen of Ser 
237. The O
δ of Asn104 interacts with the N
δ of Asn132 in the 
docked complex. Furthermore, N
δ of Asn104 was found to make a 
hydrogen bond with the carbonyl oxygen of the acylamide side 
chain of cefotaxime (Figure 2). In this way, we found that a total of 
7 hydrogen bonds are crucial for the correct positioning of 
cefotaxime within the active site of CTX-M-15 enzyme.A 
noteworthy relationship between total interaction energy (Etotal) and 
cefotaxime (MICs) of the blaCTX-M-15  positive study strains was 
observed. Cefotaxime MICs increased with the increasing negative 
value of interaction energy, when the former was docked into the 
modelled CTX-M-15 structures of the respective strains (Figure 1d). 
It can be explained by the fact that higher negative interaction 
energy for the enzyme-antibiotic complex is an indicator of more 
stable and effective interaction between the two during binding. A 
more stable and better fitting of the β-lactam antibiotic (cefotaxime) 
into the active site of the CTX-M-15 enzyme would ensure an easy 
hydrolysis of the drug. This is in coherence with one of our earlier 
observations in which we performed docking of the enzyme Sme1 
with different carbapenems to compare their effectiveness against 
Sme1 producing bacteria [18]. It was observed that the imipenem-
Sme1 complex was far more stable than the complex involving 
doripenem. This suggested an easier hydrolysis of imipenem by 
Sme-1 and a poor hydrolysis of doripenem. This was strongly 
supported by the experimental studies that suggested a better 
activity of doripenem over other carbapenems against 
carbapenemase producing bacteria [19]. Moreover, in a similar 2009 
study authors have used interaction energies of docking to compare 
the efficacy of different neuraminidase inhibitors against newly 
evolved strains of H1N1 viruses [20]. It is important to mention 
here that more experimental studies are needed to establish a precise 
relationship between MIC and interaction energy. We admit the 
limitation of the present study that we could not narrow down to a 
possible “energy-concentration pair” that produced effective 
interaction between the discussed enzyme and substrate.   
 
Conclusion: 
To the best of our knowledge we are the first to report results of 
docking between CTX-M-15 (receptor) and cefotaxime (ligand). 
Moreover, this is the first study to hypothesize a possible 
relationship between ‘interaction energy of the docked enzyme-
antibiotic complex’ and ‘minimum inhibitory concentration (MIC) 
of the antibiotic against the bacteria producing that enzyme’. In 
conclusion, the present study reveals that the amino acid residues 
Asn 104, Asn132, Gly 227, Thr 235, Gly 236, and Ser237 are 
responsible for positioning cefotaxime into the active site of the 
CTX-M-15 enzyme. A total of 7 hydrogen bonds are crucial for the 
correct positioning of cefotaxime within the active site of CTX-M-
15 enzyme. Cefotaxime MICs for the CTX-M-15-producers 
increased with the increasing negative interaction energy for the 
enzyme-antibiotic complex. Researchers are expected to duly utilize 
this information for designing more potent and versatile CTX-M-
inhibitors as well as new drugs resistant to hydrolysis by CTX-M 
enzymes. Scope is still left to determine the 3D structures of the 
rapidly emerging variants of CTX-M by X-ray crystallography. 
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Supplementary material: 
 
Table 1: Characteristics of gene sequences, modelled enzymes and enzyme-drug complexes along with cefotaxime and ceftazidime minimum inhibitory concentration (MIC)-values for E. coli strains.  *Not found/Not 
calculated by software. 
 
Interaction energy with 
cefotaxime       (kJ/mol) 
MIC (mg/L)  Strain 
No. 
Accession no. of 
reference strain used for 
alignment 
Point 
mutation 
(s) 
Amino acid 
substitution 
(s) 
Substitution(s) present in secondary 
structure (Hydrophobicity/ Ribbon 
size/ pKa) 
PDB ID of the 
temp-late retrie-
ved for mod-elling 
E-total      E-shape E-force Cefo-
taxime 
Ceft-
azidime 
Genbank Accession 
no. for genes (This 
study) 
D8  EU979558.1          262C→A, 
265A→G 
Pro88Thr, 
Asn89Asp 
Turn (-0.7/0.225/*), Turn 
(-3.5/0.225/3.9) 
1iysA   -184.6 -163.6 -21 128  64  FJ997864
D183  EU979558.1           
                
                
              
       
*  *  *  1iysA -189.49  -181.05  -8.44  128 64 FJ997865
D253  EU979558.1 * * * 1iysA -221.51  -208  -13.51  256 32 FJ997866
D281  EU979558.1 * * * 1iysA -168.17  -147.5  -20.67  64 32 GQ145220
D282  EU979558.1 * * * 1iysA -179.24  -150.42  -28.82  64 64 GQ174503
D295  EU979558.1 689G→C Val230Leu Sheet  (3.8/1.3/*) 1iysA         
         
-259.37  -243.46  -15.91  512 64 GQ145221
D296  EU979558.1 *  *  *  1iysA -200.32  -191.39  -8.93  256 32 GQ174504